Evergreen Therapeutics Announces Positive Phase II ClearMEMory Study Results: AI-enabled Drug EG-501 Demonstrates Significant Efficacy in Treating Lupus-Related Cognitive Impairment
Evergreen Therapeutics recently announced Phase II clinical study data for its investigational drug EG-501, developed with deep application of Artificial Intelligence (AI) technology. EG-501 is designed to treat cognitive impairment caused by Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). As an AI-enabled, first-in-disease therapy for this indication, EG-501's research findings further validate the immense potential of the "AI + Drug R&D" model. 01 BACKGROUNDSystemic Lupus Erythematosus (SLE) is a complex, autoimmune-mediated diffuse connective tissue disease affecting millions globally, with an increasing incidence. Cognitive impairment (CI) is one of the most common clinical manifestations of SLE, severely impacting patients' daily function and social engagement. In
